1,378 Amgen Inc. $AMGN Shares Purchased by New York Life Investment Management LLC

New York Life Investment Management LLC boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 1.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 88,055 shares of the medical research company’s stock after buying an additional 1,378 shares during the quarter. New York Life Investment Management LLC’s holdings in Amgen were worth $37,116,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. 71 West Capital Partners lifted its position in shares of Amgen by 7.9% in the third quarter. 71 West Capital Partners now owns 3,914 shares of the medical research company’s stock worth $1,650,000 after buying an additional 288 shares during the last quarter. Pinion Investment Advisors LLC bought a new stake in shares of Amgen during the 3rd quarter worth about $207,000. Leuthold Group LLC boosted its stake in shares of Amgen by 9.2% during the 3rd quarter. Leuthold Group LLC now owns 22,409 shares of the medical research company’s stock worth $9,446,000 after acquiring an additional 1,897 shares in the last quarter. Fulcrum Asset Management LLP boosted its stake in shares of Amgen by 65.5% during the 3rd quarter. Fulcrum Asset Management LLP now owns 4,428 shares of the medical research company’s stock worth $1,876,000 after acquiring an additional 1,752 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its holdings in shares of Amgen by 16.9% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 112,799 shares of the medical research company’s stock valued at $45,940,000 after acquiring an additional 16,327 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

  • Positive Sentiment: New data presented at the American Heart Association’s 2026 Scientific Sessions strengthened the case for earlier and more intensive Repatha treatment. Amgen cited an analysis finding the drug highly cost-effective in high-risk patients without a prior heart attack or stroke, and a long-term analysis associating it with a 29% lower risk of major cardiovascular events in patients with existing cardiovascular disease. These findings could support Repatha’s clinical profile and adoption, although the reported evidence includes an external-control analysis. Read article
  • Neutral Sentiment: Investors are watching for ACR conference data on dazodalibep. The coverage frames the results as a test for the program, but the provided reports do not disclose findings, so the clinical and stock impact remains uncertain. Read article
  • Neutral Sentiment: Recent coverage also compares Amgen’s dividend income and valuation with Regeneron’s faster growth, while another report says analyst views on Amgen are mixed. Neither item provides a specific new forecast or rating change that clearly shifts the near-term outlook. Read article

Amgen Price Performance

NASDAQ:AMGN opened at $465.23 on Wednesday. The company has a debt-to-equity ratio of 3.60, a current ratio of 1.48 and a quick ratio of 1.20. Amgen Inc. has a one year low of $312.39 and a one year high of $483.99. The company has a fifty day moving average price of $423.79 and a 200 day moving average price of $379.39. The stock has a market cap of $251.65 billion, a P/E ratio of 26.99, a PEG ratio of 3.25 and a beta of 0.43.

Amgen (NASDAQ:AMGN – Get Free Report) last posted its quarterly earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.79 by $0.66. The company had revenue of $10.37 billion for the quarter, compared to analyst estimates of $10.07 billion. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The business’s quarterly revenue was up 8.5% on a year-over-year basis. During the same period last year, the business posted $5.64 EPS. Analysts anticipate that Amgen Inc. will post 23.33 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be paid a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Friday, November 20th. Amgen’s dividend payout ratio (DPR) is presently 58.47%.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on AMGN. Oppenheimer reissued an “outperform” rating on shares of Amgen in a research note on Friday, October 23rd. Sanford C. Bernstein boosted their target price on Amgen from $345.00 to $400.00 and gave the stock a “market perform” rating in a report on Wednesday, November 4th. TD Cowen upped their target price on Amgen from $452.00 to $531.00 and gave the stock a “buy” rating in a research report on Wednesday, November 4th. Canaccord Genuity Group increased their price target on Amgen from $384.00 to $440.00 and gave the company a “hold” rating in a report on Wednesday, November 4th. Finally, Cantor Fitzgerald increased their price target on Amgen from $440.00 to $465.00 and gave the company a “neutral” rating in a report on Wednesday, November 4th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eighteen have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, Amgen has an average rating of “Hold” and a consensus target price of $422.76.

Check Out Our Latest Analysis on Amgen

Insider Buying and Selling at Amgen

In related news, SVP Rachna Khosla sold 1,252 shares of Amgen stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $416.43, for a total transaction of $521,370.36. Following the sale, the senior vice president directly owned 6,404 shares of the company’s stock, valued at $2,666,817.72. This trade represents a 16.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.85% of the company’s stock.

Amgen Profile

(Free Report)

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.

Read More

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.